AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB 001 at the 66th American Society of Hematology (ASH) ...

Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...

Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...

Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...

Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...

As we are a pretty opinionated bunch here at PharmaTimes, we like it when contributors are prepared to stand up and express a viewpoint. For the past few months, our expanded SmartViews section has ...

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute ...

Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in Springfield, NJ, USA, have announced the expansion of their collaborative research agreement. This partnership seeks ...